Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
McCarthy G, Young K, Madin-Warburton M, Mantaian T, Brook E, Metcalfe K, Mikelson J, Xu R, Seyla-Hammer C, Aguiar-Ibáñez R, Amonkar M.
McCarthy G, et al. Among authors: xu r.
J Med Econ. 2024 Jan-Dec;27(1):279-291. doi: 10.1080/13696998.2024.2311507. Epub 2024 Feb 19.
J Med Econ. 2024.
PMID: 38293714
Free article.